TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35043428

Group type: EXPERIMENTAL
Intervention: Venetoclax plus hypomethylating agent (HMA)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Venetoclax plus low-dose cytarabine (LDAC)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Venetoclax plus HMA
Number of subjects: 771

Group type: COMPARATOR
Intervention: Venetoclax plus LDAC
Number of subjects: 771

Group type: COMPARATOR
Intervention: Venetoclax
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 771
Study: 33682260

Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (MCS) devices
Number of subjects: 0
Study: 34514959

Group type: EXPERIMENTAL
Intervention: Illusion group (watched own finger joint movement video image and induced kinesthetic illusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Illusion group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motor execution group
Number of subjects: 30
Study: 32247156

Group type: EXPERIMENTAL
Intervention: E‐PRE‐DELIRIC score
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: PRE‐DELIRIC score
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: E‐PRE‐DELIRIC and PRE‐DELIRIC scores
Number of subjects: 1506
Study: 33743831

Group type: EXPERIMENTAL
Intervention: Oral isotretinoin treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (local treatment)
Number of subjects: 60
Study: 32326621

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1200 IU) for 26 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 34814867

Group type: EXPERIMENTAL
Intervention: cinpanemab, a monoclonal antibody against alpha‐synuclein
Number of subjects: 482
Study: 32054543

Group type: EXPERIMENTAL
Intervention: PS + FO (3.3 g/d PS and 450 mg EPA + 1500 mg DHA/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PS (3.3 g/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: FO (450 mg EPA + 1500 mg DHA/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: PO (placebo)
Number of subjects: 96
Study: 33945036

Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block (GONB) with local anesthetic and triamcinolone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Detoxification without GONB (Control group)
Number of subjects: 54
Study: 32504217

Group type: EXPERIMENTAL
Intervention: Auto-cleaning device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual toothbrushing
Number of subjects: 20
Study: 32241780

Group type: EXPERIMENTAL
Intervention: Tolvaptan + Statin
Number of subjects: 2815

Group type: COMPARATOR
Intervention: Placebo + Statin
Number of subjects: 2815
Study: 35022546

Group type: EXPERIMENTAL
Intervention: Digital intervention group
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: Digital intervention + face-to-face counselling group
Number of subjects: 2684

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: No attempts to lose weight
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: 1-2 attempts
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: 3 or more attempts
Number of subjects: 2684
Study: 32776347

Group type: EXPERIMENTAL
Intervention: Home parenteral nutrition (PN) or customized intravenous fluid (IVF) support for IBD patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group of IBD patients
Number of subjects: 25
Study: 34453208

Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed® Advanced Hybrid Closed-Loop (AHCL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM)
Number of subjects: 59
Study: 32035738

Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills (client‐centered communication approach)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no Healthy Conversation Skills)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills
Number of subjects: 70
Study: 35084022

Group type: EXPERIMENTAL
Intervention: Remdesivir plus Dexamethasone
Number of subjects: 151

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 151
Study: 33992038

Group type: EXPERIMENTAL
Intervention: Supplemental feeding tube device (SFTD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bottle method (control)
Number of subjects: 46
Study: 35917660

Group type: EXPERIMENTAL
Intervention: Expressive writing pre-wounding
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 122

Group type: COMPARATOR
Intervention: Healed wounds
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 122
Study: 34534770

Group type: EXPERIMENTAL
Intervention: Dietary self-monitoring via MyFitnessPal for one month
Number of subjects: 20
Study: 35227242

Group type: EXPERIMENTAL
Intervention: Respite care (home-based services)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 32197714

Group type: EXPERIMENTAL
Intervention: Mind-body medicine use among women with gynecological cancer
Number of subjects: 26742

Group type: COMPARATOR
Intervention: Mind-body medicine use among women without gynecological cancer
Number of subjects: 26742
Study: 34425226

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone enanthate per week in sesame oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (sesame seed oil only)
Number of subjects: 50
Study: 32073662

Group type: EXPERIMENTAL
Intervention: Favorable high-risk disease
Number of subjects: 3033
Study: 35146830

Group type: EXPERIMENTAL
Intervention: iNPWT (PICO™, Smith&Nephew)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard dressing (Steri‐Strips™) with suction drain
Number of subjects: 80
Study: 32490771

Group type: EXPERIMENTAL
Intervention: Intraarticular catheter + anesthetics (bupivacaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraarticular catheter + placebo (physiological serum)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subfascial catheter + anesthetics (bupivacaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subfascial catheter + placebo (physiological serum)
Number of subjects: 100
Study: 35405085

Group type: EXPERIMENTAL
Intervention: Standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily)
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Standard of care plus abiraterone
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m2 once every 3 weeks)
Number of subjects: 1173
Study: 33484566

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including training workshops for medical staff and telemedicine technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33249812

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (personalized guidance via WeChat Mini Program Rehabilitation Cloud Platform)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mobile health intervention
Number of subjects: 125
Study: 36493840

Group type: EXPERIMENTAL
Intervention: Intensive BP lowering strategy (Systolic BP target <120 mm Hg)
Number of subjects: 11255

Group type: COMPARATOR
Intervention: Standard BP lowering strategy (Systolic BP target <140 mm Hg)
Number of subjects: 11255

Group type: EXPERIMENTAL
Intervention: Intensive BP lowering strategy
Number of subjects: 11255

Group type: COMPARATOR
Intervention: Standard BP lowering strategy
Number of subjects: 11255
Study: 33154570

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 593

Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 593
Study: 32540720

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS combined with robotic-assisted gait training (RAGT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Baseline high-beta EEG oscillations power
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Decreases in relative high-beta power and increases in beta power during walking
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: tDCS combined with robotic training
Number of subjects: 39
Study: 33933596

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 33785481

Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide plus zotiraciclib
Number of subjects: 53

Group type: COMPARATOR
Intervention: Metronomic temozolomide plus zotiraciclib
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Zotiraciclib
Number of subjects: 53
Study: 33979763

Group type: EXPERIMENTAL
Intervention: TNX-102 SL 5.6 mg
Number of subjects: 231

Group type: COMPARATOR
Intervention: TNX-102 SL
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: TNX-102 SL 2.8 mg
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 32266856

Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Within-person depressive symptoms
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Higher levels of within-person perceived social support
Number of subjects: 455
Study: 34687810

Group type: EXPERIMENTAL
Intervention: Toothbrush A (medium-hard, compact head)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrush B (medium-hard, regular head)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrush C (medium-hard, compact head)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Toothbrush D (soft, compact head)
Number of subjects: 80
Study: 34766453

Group type: EXPERIMENTAL
Intervention: Nurse-led counselling and education (two face-to-face sessions, two telephone sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 120
Study: 32447442

Group type: EXPERIMENTAL
Intervention: Early drainage by ureteral stenting (within 48 hours after admission)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Early drainage
Number of subjects: 238
Study: 33208658

Group type: EXPERIMENTAL
Intervention: Home biofeedback
Number of subjects: 54

Group type: COMPARATOR
Intervention: PFPT
Number of subjects: 54
Study: 32497023

Group type: EXPERIMENTAL
Intervention: l-Arginine supplementation (0.05 mg/kg orally, twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: l-Arginine supplementation
Number of subjects: 50
Study: 35748393

Group type: EXPERIMENTAL
Intervention: Yohimbine (10 mg, n=17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sulpiride (200 mg, n=16)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 51
Study: 33901017

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study: 35319478

Group type: EXPERIMENTAL
Intervention: Social media-based diabetes educational program (51 videos, 3 months duration, 2-3 videos/week, care messages every 2 weeks)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Social media-based diabetes educational program
Number of subjects: 181
Study: 34410410

Group type: EXPERIMENTAL
Intervention: High-protein (HP) meal
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-protein/high-fat (HPHF) meal
Number of subjects: 21
Study: 34240571

Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency (RF) treatment of the nasal valve
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 118
Study: 32101259

Group type: EXPERIMENTAL
Intervention: New LDL-C equation
Number of subjects: 8656
Study: 35352499

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32129954

Group type: EXPERIMENTAL
Intervention: Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam
Number of subjects: 426
Study: 35593612

Group type: EXPERIMENTAL
Intervention: Peer education nursing skills (experimental group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional education model (control group)
Number of subjects: 92
Study: 33069317

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144
Study: 35819779

Group type: EXPERIMENTAL
Intervention: tDCS stimulation (anodal over left dorsolateral prefrontal cortex) for 13 consecutive days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (tDCS and Sham)
Number of subjects: 49
Study: 34049770

Group type: EXPERIMENTAL
Intervention: Intradermal acetylcholine (ACh) injection
Number of subjects: 38
Study: 32602830

Group type: EXPERIMENTAL
Intervention: MBT-DH
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: MBT-IOP
Number of subjects: 114
Study: 34174326

Group type: EXPERIMENTAL
Intervention: Dual-task with blood flow restriction (DTBFR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dual-task (DT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 24
Study: 34252906

Group type: EXPERIMENTAL
Intervention: Group-based psychosocial interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger Adults (YA)
Number of subjects: 0
Study: 32052468

Group type: EXPERIMENTAL
Intervention: Normal speech condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word-salad condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudo-words condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (spectrally rotated version of normal speech)
Number of subjects: 0
Study: 34433510

Group type: EXPERIMENTAL
Intervention: CV + HIIT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HIIT + CV
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: COMPARATOR
Intervention: CV
Number of subjects: 46
Study: 33745757

Group type: EXPERIMENTAL
Intervention: Case management, peer recovery coaching and overdose education and naloxone distribution (CM/PRC + OEND)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Overdose education and naloxone distribution (OEND) alone
Number of subjects: 1000
Study: 34923848

Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: variant transthyretin amyloidosis)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: wild-type transthyretin amyloidosis)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: NYHA class I and II)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: NYHA class III)
Number of subjects: 353
Study: 34048027

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 4465

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4465

Group type: COMPARATOR
Intervention: Combined analysis of anastrozole and exemestane
Number of subjects: 4465
Study: 32113192

Group type: EXPERIMENTAL
Intervention: Bubble-PEP
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ACBT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 35505467

Group type: EXPERIMENTAL
Intervention: Keverprazan 20 mg once daily
Number of subjects: 238

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 238
Study: 35321130

Group type: EXPERIMENTAL
Intervention: Hot normobaric hypoxic (HH; 35℃, FiO2 14.5%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxic (HYP; 23℃, FiO2 14.5%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxic (NOR; 23℃, 50%, FiO2 20.9%)
Number of subjects: 9
Study: 35303958

Group type: EXPERIMENTAL
Intervention: NIV with Owner mask (NIV Owner COVID Group, n = 63)
Number of subjects: 383

Group type: COMPARATOR
Intervention: NIV with conventional orofacial mask (NIV Orofacial COVID Group, n = 63)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: NIV with Owner mask (NIV Owner Non-COVID Group, n = 97)
Number of subjects: 383

Group type: COMPARATOR
Intervention: NIV with conventional orofacial mask (NIV Orofacial Non-COVID Group, n = 97)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: NIV with Owner mask
Number of subjects: 383

Group type: COMPARATOR
Intervention: NIV with conventional orofacial mask
Number of subjects: 383
Study: 34311772

Group type: EXPERIMENTAL
Intervention: 15-min talocrural joint manual therapy plus 30-min specific task-oriented training (group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 45-min specific task-oriented training (group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 36
Study: 36007166

Group type: EXPERIMENTAL
Intervention: Self-selected music during exercise
Number of subjects: 22
Study: 33909360

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment at Guanyuan (CV 4), Shuidao (ST 28), Guilai (ST 29), Shenshu (BL 23), and Ciliao (BL 32), disperse-dense wave, 2 Hz/15 Hz frequency, once a day for 10 days per menstrual cycle for 3 menstrual cycles
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ibuprofen sustained-release capsules, 0.3 g each time, once a day for 10 days before menstruation
Number of subjects: 144
Study: 34142293

Group type: EXPERIMENTAL
Intervention: Various HIPEC regimens (specific regimens not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized medicine approaches (e.g., patient-derived tumor organoids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert consensus on HIPEC regimens
Number of subjects: 0
Study: 32009195

Group type: EXPERIMENTAL
Intervention: mepolizumab (monoclonal antibody to IL-5) as an add-on therapy to glucocorticoid treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 61
Study: 34235765

Group type: EXPERIMENTAL
Intervention: Integrated Palliative Care Outcome Scale for people with dementia (IPOS-Dem)
Number of subjects: 0
Study: 32354681

Group type: EXPERIMENTAL
Intervention: Physician-delivered step count prescription
Number of subjects: 118
Study: 35418065

Group type: EXPERIMENTAL
Intervention: Daily contact testing (DCT) using a rapid Lateral Flow Device (LFD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Self-isolation
Number of subjects: 63
Study: 33570017

Group type: EXPERIMENTAL
Intervention: D-cycloserine (250 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 32090430

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 1701129

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 1701129

Group type: COMPARATOR
Intervention: Non-diabetic patients (Control)
Number of subjects: 1701129

Group type: COMPARATOR
Intervention: Type 1 Diabetes (T1D) vs Non-diabetic
Number of subjects: 1701129

Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D) vs Non-diabetic
Number of subjects: 1701129
Study: 35320555

Group type: EXPERIMENTAL
Intervention: Alpha® ointment (Lawsonia inermis 3 g and Curcuma longa 0.15 g/30 g), applied two times daily for 4 consecutive courses of chemotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo ointment, applied two times daily for 4 consecutive courses of chemotherapy
Number of subjects: 90
Study: 35818363

Group type: EXPERIMENTAL
Intervention: Baricitinib in combination with remdesivir therapy (BCT)
Number of subjects: 891

Group type: COMPARATOR
Intervention: Remdesivir monotherapy (RMT)
Number of subjects: 891
Study: 32145827

Group type: COMPARATOR
Intervention: Intravenous paclitaxel plus ART
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Oral etoposide plus ART
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Intravenous bleomycin and vincristine plus ART
Number of subjects: 334
Study: 35751503

Group type: EXPERIMENTAL
Intervention: Gastroplasty group (GG; n = 39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (CG; n = 34)
Number of subjects: 73
Study: 33199052

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 105
Study: 33037803

Group type: EXPERIMENTAL
Intervention: Preoperative treatment with 1000 mg IV acetaminophen 20 min before surgery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postoperative treatment with 1000 mg IV acetaminophen after surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 120
Study: 32171038

Group type: EXPERIMENTAL
Intervention: NDMC 20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NDMC 60 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clonazepam 1.5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NDMC
Number of subjects: 32
Study: 34116817

Group type: EXPERIMENTAL
Intervention: Peer-led navigation intervention (SHINE), two sessions
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Peer-led navigation intervention (SHINE)
Number of subjects: 119
Study: 32353816

Group type: EXPERIMENTAL
Intervention: Family-based Mindfulness Intervention (FBMI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 51
Study: 615123829

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 6 liters per minute
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal intermittent mechanical ventilation (NIMV) at 12/5 cm H2O
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) at 5 cm H2O
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) prior to extubation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal intermittent mechanical ventilation (NIMV) with nasal clip
Number of subjects: 42
Study: 35150473

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment
Number of subjects: 29